Cytotoxic drugs can be toxic to cells - these HPAPIs (Highly Potent Active Pharmaceutical Ingredients) are difficult to handle and require specialist facilities. At Biopharma Group, we have three dedicated Category D, low bio-burden labs and one cytotoxic suite that ensure we are able to handle HPAPI samples correctly. The suites are safely contained, and in turn limit exposure, ensuring protection for both the integrity of the product or person handling them – allowing cytotoxic and sensitive samples handling to be carried out safely and efficiently.
Within each of our Category D labs and cytotoxic suite, Biopharma Group has the capability to handle:
- Small molecules - HPAPIs, toxic compounds, antibiotics, mRNA
- Large molecules - proteins, mAbs, ADCs, DNA, collagen
- Nanoparticles and viral vectors
- Advanced Therapy Medicinal Products (ATMP) - gene/ cell therapies and tissue engineering
- Biologics, including cells, stem cells, blood derivate products, human tissues
Due to the potentially harmful nature of these toxic compounds, rigorous protection measures are set in place to ensure we are fully compliant with safety, product quality and regulatory protocols.
